Skip to content

Zymeworks ZYME Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value

Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value at other companies

Zymeworks logo
ZymeworksZYME
5.6
US Foods logo
US FoodsUSFD
$8.27-46.4%
KEE
Keel Infrastructure Corp. Common StockKEEL
$1.08+4.9%
The Baldwin Insurance Group, Inc. logo
The Baldwin Insurance Group, Inc.BWIN
$44.69+40.8%
Zymeworks logo
ZymeworksZYME
8
NovaGold Resources logo
NovaGold ResourcesNG
$4.48-9.7%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue.

The official record: Zymeworks’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's sharebased compensation arrangement by sharebased payment award options nonvested options forfeited weighted average grant date fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's sharebased compensation arrangement by sharebased payment award options nonvested options forfeited weighted average grant date fair value?
Zymeworks (ZYME) reported sharebased compensation arrangement by sharebased payment award options nonvested options forfeited weighted average grant date fair value of 5.6 in Q4 2025.
What does sharebased compensation arrangement by sharebased payment award options nonvested options forfeited weighted average grant date fair value mean?
The weighted-average grant date fair value of nonvested stock options that were forfeited during the reporting period. This value assists in understanding the financial impact of employee attrition on the company's total share-based compensation expense.